



(51) International Patent Classification:

C07K 14/705 (2006.01) A61K 39/00 (2006.01)

Published:

— without international search report and to be republished upon receipt of that report (Rule 48.2(g))

(21) International Application Number:

PCT/US2023/010518

(22) International Filing Date:

10 January 2023 (10.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/298,141 10 January 2022 (10.01.2022) US

(71) Applicants: **2SEVENTY BIO, INC.** [US/US]; 60 Binney Street, Cambridge, MA 02142 (US). **REGENERON PHARMACEUTICALS, INC.** [US/US]; 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(72) Inventor; and

(71) Applicant: **ALBERSHARDT, Tina** [US/US]; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(72) Inventors: **PARSONS, Geoffrey Blackburn**; 17 Castleton Street, Jamaica Plain, MA 02130 (US). **DILILLO, David**; c/o Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(74) Agent: **CLARKE, Marcie B.** et al.; McCarter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: MUC16 CHIMERIC ANTIGEN RECEPTORS

(57) Abstract: The present disclosure provides chimeric antigen receptors (CARs) targeting MUC16, genetically modified immune effector cells, and use of these compositions to treat cancer.

